KRAS mutant lung cancer comprises 25-30% of lung adenocarcinomas and unfortunately no effective treatment is currently available for this sub-type of non-small cell lung cancer (NSCLC). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.